厄洛替尼联合全脑放疗对非小细胞肺癌脑转移患者的临床疗效及预后影响

Prognosis and clinical effect of erlotinib combined WBRT in patients with brain metastases of non-small cell lung cancer

目的探讨厄洛替尼联合全脑放疗（whole brain radiotherapy,WBRT）治疗非小细胞肺癌（non-small cell lung cancer,NSCLC）脑转移患者的临床效果及预后影响。方法选取2013年9月-2015年5月丽水市中心医院收治的NSCLC脑转移患者100例,根据患者是否使用厄洛替尼分为对照组54例和观察组46例,2组均给予WBRT治疗,对比2组患者的近期效果、远期预后及不良反应发生率。结果观察组的缓解率52.17%显著高于对照组27.78%,观察组总有效率91.30%显著高于对照组72.22%,差异均具有统计学意义（P〈0.05）;观察组的1年生存率52.17%（24/46）显著高于对照组29.63%（16/54）,观察组中位生存时间9.0个月显著高于对照组6.0个月,差异均具有统计学意义（P〈0.05）;2组治疗过程中不良反应发生率差异均无统计学意义。结论厄洛替尼联合WBRT治疗NSCLC脑转移患者能够提高近期疗效及远期预后的效果。

Objective To investigate the prognosis and clinical effect of erlotinib combined WBRT in patients with brain metastases of non-small cell lung cancer. Methods 100 cases of NSCLC patients from September 2013 to May 2015 in our hospital with brain metastases were collected,according to whether patients with erlotinib were divided into control group 54 cases and observation group 46 cases,both two groups were given WBRT treatment,the short-term effects,long-term prognosis and adverse reactions were compared between the two groups. Results The remission rate in observation group 52. 17% was significantly higher than control group 27. 78%,the total effective rate in observation group 91. 30% was significantly higher than control group 72. 22%,the difference was statistically significant（ P〈0. 05）; The 1 year survival rate in observation group 52. 17%（ 24 /46）was significantly higher than control group 29. 63%（ 16 /54）,the median survival time in observation group 9. 0 months was significantly higher than control group 6. 0 months,the difference was statistically significant（ P〈0. 05）; There was no significant difference between the two groups in the incidence of adverse reactions. Conclusion Erlotinib combined with WBRT in the treatment of NSCLC patients with brain metastases can improve the prognosis of curative effect and long-term effect.